- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
Demo Project
Open Label
Principal Investigator(s)
Steven Shoptaw, PhD; Manya Magnus, PhD, MPH; Lisa Hightow-Weidman
Objective
Designed to assess the initiation, acceptability, safety, and feasibility of PrEP for Black MSM (BMSM). A subset of participants will also be recruited to participate in qualitative interviews about facilitators and barriers regarding PrEP. The study will recruit HIV-uninfected BMSM at risk for HIV infection in three US Cities. Enrollment will include those aged 18 and over with an effort to recruit an equal number of BMSM under age 25 and over age 25 with a total of 225 participants (75 per site).
*Results presented at the AIDS 2016 conference in 2016 demonstrated that PrEP was accepted by 178 (79 percent) study participants. Among those continuing PrEP at week 26, 62 percent self-reported high adherence. Drug concentrations consistent with taking pills at least four times a week were also observed in approximately the same proportion of participants. The protocol chair, Darrell P. Wheeler, Ph.D., M.P.H, stated, “The new report from HPTN 073 supports the primary research finding of high acceptability and uptake of oral PrEP among BMSM when combined with coordinated counseling,”*Prevention Option(s)
PrEP
Arms and Assigned Interventions
Description
All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
Products
TDF/FTC (Truvada)
Official Code
Trial Sponsors
HIV Prevention Trials Network; NIAID/NIH
August 2013
September 2015
Enrollment
225
18
Years
Population
MSM
Sites
UCLA Vine Street Clinic
Los Angeles, California
United States of America
George Washington University CRS
Washington, District of Columbia
United States of America
UNC CRS
Chapel Hill, North Carolina
United States of America